The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
Eric Jay Small
Consultant or Advisory Role - Dendreon
Raymond S. Lance
No relevant relationships to disclose
Charles H. Redfern
No relevant relationships to disclose
Frederick E. Millard
Research Funding - Dendreon
Thomas A. Gardner
Honoraria - Dendreon
Lawrence Ivan Karsh
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Research Funding - Urology Center of Colorado
Nancy Ann Dawson
Honoraria - Dendreon
Research Funding - Dendreon
Candice McCoy
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Andrew Stubbs
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Corazon P. dela Rosa
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Neal D. Shore
Consultant or Advisory Role - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Medivation; Millennium